Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -24.0%
- Operating Margin Trend -3314.63 pp/yr
CLDX
Celldex Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 17.3 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -30.9%
- 5yr Share-Count CAGR 17.5%
Growth Quality
Weight: 15%
F
12
- 5yr Revenue CAGR -27.4%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -4783.8%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 24.66
Stability
Weight: 15%
D-
30
- Negative-Revenue Years (5) 3/5
- Piotroski F-Score 2
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 2 trimmed.
- Holders
- 2
- Avg Δ position
- -83.1%
- New buys
- 0
- Full exits
- 0